🇺🇸 FDA
Patent

US 10137186

Compositions and methods for live, attenuated alphavirus formulations

granted A61KA61K2039/5254A61K39/12

Quick answer

US patent 10137186 (Compositions and methods for live, attenuated alphavirus formulations) held by Takeda Vaccines, Inc. expires Mon Nov 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Vaccines, Inc.
Grant date
Tue Nov 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K2039/5254, A61K39/12, A61K47/22, A61K47/26